Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

US Court rules in favour of Zydus in ulcerative colitis drug patent case

It ruled that Zydus' generic version of Lialda (mesalamine) does not infringe patent of Shire

BS B2B Bureau  |  Mumbai 

Biocompatibles pleads guilty to misbranding, agrees to pay $ 36 mn

The US Court of Federal Circuit has affirmed judgement in favour of (USA) Inc, the US-based subsidiary of Cadila, holding that its proposed generic version of (mesalamine) does not infringe US Patent (No 6,773,720) of was the first pharmaceutical company to file an abbreviated new drug application (ANDA) for a generic version of

is indicated for the induction of remission of active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC. Ulcerative colitis - a chronic inflammatory bowel disease that causes inflammation in the digestive tract - affects approximately 700,000 people in the US.

Earlier, in September 2016, the US District Court for the District of Delaware ruled that a proposed generic made by does not infringe US Patent No 6,773,720. Following this ruling, had appealed to the Court of Appeals to the Federal Circuit.

With the Court of Appeals ruling in flavour, the company has taken a major step towards providing a generic version of (mesalamine) in the US. has reported annual sales of $ 714 million for this product in 2016 in the US.

Pankaj Patel, chairman and managing director, Cadila, said, "We welcome this decision which is a positive step and will help us further our mission of making available high-quality, affordable generic products to our customers and their patients."

RECOMMENDED FOR YOU

US Court rules in favour of Zydus in ulcerative colitis drug patent case

It ruled that Zydus' generic version of Lialda (mesalamine) does not infringe patent of Shire

It ruled that Zydus' generic version of Lialda (mesalamine) does not infringe patent of Shire
The US Court of Federal Circuit has affirmed judgement in favour of (USA) Inc, the US-based subsidiary of Cadila, holding that its proposed generic version of (mesalamine) does not infringe US Patent (No 6,773,720) of was the first pharmaceutical company to file an abbreviated new drug application (ANDA) for a generic version of

is indicated for the induction of remission of active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC. Ulcerative colitis - a chronic inflammatory bowel disease that causes inflammation in the digestive tract - affects approximately 700,000 people in the US.

Earlier, in September 2016, the US District Court for the District of Delaware ruled that a proposed generic made by does not infringe US Patent No 6,773,720. Following this ruling, had appealed to the Court of Appeals to the Federal Circuit.

With the Court of Appeals ruling in flavour, the company has taken a major step towards providing a generic version of (mesalamine) in the US. has reported annual sales of $ 714 million for this product in 2016 in the US.

Pankaj Patel, chairman and managing director, Cadila, said, "We welcome this decision which is a positive step and will help us further our mission of making available high-quality, affordable generic products to our customers and their patients."

image
Business Standard
177 22

US Court rules in favour of Zydus in ulcerative colitis drug patent case

It ruled that Zydus' generic version of Lialda (mesalamine) does not infringe patent of Shire

The US Court of Federal Circuit has affirmed judgement in favour of (USA) Inc, the US-based subsidiary of Cadila, holding that its proposed generic version of (mesalamine) does not infringe US Patent (No 6,773,720) of was the first pharmaceutical company to file an abbreviated new drug application (ANDA) for a generic version of

is indicated for the induction of remission of active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC. Ulcerative colitis - a chronic inflammatory bowel disease that causes inflammation in the digestive tract - affects approximately 700,000 people in the US.

Earlier, in September 2016, the US District Court for the District of Delaware ruled that a proposed generic made by does not infringe US Patent No 6,773,720. Following this ruling, had appealed to the Court of Appeals to the Federal Circuit.

With the Court of Appeals ruling in flavour, the company has taken a major step towards providing a generic version of (mesalamine) in the US. has reported annual sales of $ 714 million for this product in 2016 in the US.

Pankaj Patel, chairman and managing director, Cadila, said, "We welcome this decision which is a positive step and will help us further our mission of making available high-quality, affordable generic products to our customers and their patients."

image
Business Standard
177 22